1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Deccan Health Care Ltd.

Deccan Health Care Ltd.

BBSE:DECCAN
12.73
INR
+0.51
(+4.17%)
1.05EPS
12.81P/E
331.39MMarket Cap
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
10.28
18.67
29.06
31.43
26.88
21.49
21.11
35.3
32.1
34.88
33.12
33.65
Basic EPS, GAAP
2.25
6.07
10.26
10.29
6.42
0.25
0.21
0.24
0.8
0.54
1.01
1.05
Free Cash Flow per Basic Share
1.94
0.56
5.94
-1.29
-0.49
0.04
-0.44
-5.3
-6.74
-3.05
-2.5
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
5.35
14.09
29.39
42.09
48.51
48.34
48.96
47.86
47.56
45.42
44.55
- -
Tangible Book Value per Share
5.35
14.09
29.39
42.09
48.51
48.3
48.94
47.85
47.55
45.41
44.54
- -
Basic Weighted Avg Shares
16
16
13
14
16
16
16
13
19
22
25
24
Sales/Revenue/Turnover
162
293
378
442
422
338
332
450
597
751
819
818
Operating Margin (%)
32.16
39.59
33.77
35.07
24.28
4.52
12.53
1.33
3.83
2.26
5.52
4.64
Depreciation Expense
12
12
13
13
14
15
15
14
15
15
15
14
Net Income, GAAP
35
95
134
145
101
4
3
3
15
12
25
25
Effective Tax Rate (%)
0.19
- -
- -
0.59
0.44
24.89
40.53
30.38
32.58
28.92
23.83
23.45
Profit Margin (%)
21.92
32.51
35.32
32.73
23.88
1.15
0.97
0.68
2.5
1.54
3.04
3.11
Working Capital
71
158
253
435
523
537
574
640
807
905
957
- -
LT Debt
139
108
85
9
9
7
9
14
17
9
27
- -
Total Equity
84
221
462
661
762
766
769
816
969
1,064
1,103
- -
Return on Invested Capital (%)
- -
- -
- -
24.35
13.93
0.57
0.45
0.46
1.67
1.16
2.45
- -
Return on Capital (%)
- -
- -
- -
24.82
14.1
0.58
0.5
0.45
1.68
1.16
2.37
- -
Return on Common Equity (%)
- -
62.46
39.11
25.78
14.17
0.51
0.42
0.39
1.67
1.14
2.3
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
13
- -
LT Borrowings
- -
27
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
25
25
25
Market Capitalization
367
170
331

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
1,297
- -
Cash, Cash Equivalents & STI
- -
17
- -
Accounts Receivable, Net
- -
170
- -
Inventories
- -
470
- -
Total Current Liabilities
- -
340
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
13
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
36.97%
7.73%
3.64%
Free Cash Flow
11.4%
-61.03%
-5.8%
Net Income, GAAP
54.88%
91.51%
114.69%
Sales/Revenue/Turnover
20.43%
20.28%
9.12%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
151
188
204
207
751
2026
221
214
174
210
819
2027
221
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.18
0.26
0.07
0.05
0.54
2026
0.1
0.37
0.41
0.14
1.01
2027
0.12
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Minto Purushotam Gupta
Full Time Employees
80
Sector
Health technology
Industry
Pharmaceuticals: other
Address
6-3-347/17/5/A/Back position Hyderabad TG India 500082
IPO Date
Dec 31, 2018
Website
deccanhealthcare.co.in
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Deccan Health Care Limited (DECCAN.BO) manufactures and markets nutraceuticals and wellness products focused on fast-moving consumer healthcare (FMCH), including food pills and meals addressing 52 consumer wellness goals to prevent over 200 diseases, disorders, and disabilities from micronutritional deficiencies; its portfolio encompasses over 1,500 market-ready products across categories such as immune support, cardiovascular health, digestive aids, personal care, weight management, vitamins and minerals, probiotics, proteins and peptides, omega fatty acids, and general health solutions in forms including capsules, tablets, soft gels, powders, liquids, and gummies; key brands and offerings under Be Young include Stay Young Food Pill, Stay Young Protein Shake, Stay Young Slim Meal, OmegaMax TOTAL, OxyFlax NANO, Lignofiax, Neurovit MC, CardoDecc, Ostohealth, Orthomega, O3D3, ReactiveGo, Maxicare, ProstaDecc, and ayurvedic products like Herbs Cough Syrup, Nutrient Tulsi Honey, and Omega 3 supplements, sold primarily through e-commerce platforms such as www.beyoungstore.com. Founded in 1996 and headquartered in Hyderabad, Telangana, India, the company operates globally with presence in regions including Africa (Botswana, Kenya, Tanzania, Mauritius, Ethiopia, Mozambique, South Africa), Asia and Middle East (India, Nepal, Kazakhstan, Yemen, Philippines), Europe (United Kingdom, Russia, Ukraine), North America (United States), and Australasia. In recent developments, Deccan Health Care converted multiple tranches of convertible warrants into equity shares in 2024 and 2025, including allotments to Focal Ventures Private Limited and Krishna Ventures in April and December 2024; the company appointed Mohak Gupta as Additional Executive Director and extended its POSHAN MAITRI project under POSHAN Abhiyaan with the Himachal Pradesh government in September 2025; it reported net profit growth of 71.70% to Rs 0.91 crore for the quarter ended September 2025, with sales up 13.71% to Rs 21.40 crore, alongside consolidated financial results for March 2025 showing revenue of Rs 75.06 crore and profit of Rs 1.16 crore; promoter holding decreased to 18.4% amid low but stable debt levels and a strong balance sheet.